Breaking Down Preclinical Characterization of STRO-227 Dual Payload ADC to Evaluate Efficacy & Safety in ADC Resistance Models - 17th World ADC San Diego

Your Flagship Event Driving ADC Innovation, Insights & Connections

Register by Friday, August 7 & Save up to $600

Day

Hour

Minute

Second

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Iza-Bren Is Approved in China for Recurrent/Metastatic Nasopharyngeal Carcinoma
Novartis to acquire Myricx Bio for up to $1.5B, adding cancer-fighting ADC payload platform
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war
J&J makes $1B upfront bet on emerging DAC space by netting Firefly Bio

Breaking Down Preclinical Characterization of STRO-227 Dual Payload ADC to Evaluate Efficacy & Safety in ADC Resistance Models

2:30 pm - Wednesday 14th October 2026

Addressing rationale for dual payload ADC development to combat acquired resistance to single payload ADCs
Laying out the preclinical profile of STRO-227, highlighting efficacy in models of ADC resistance and NHP safety data
Looking ahead to STRO-227 IND filing and clinical strategy to benefit patients

Speakers:

Daniel Calarese

Daniel Calarese

Executive Director - Drug Discovery & Innovation

Sutro Biopharma